Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04049162
Other study ID # Pro00101714
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 20, 2019
Est. completion date November 22, 2022

Study information

Verified date January 2023
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recent evidence suggests that increased berry intake results in a variety of health benefits, across multiple health domains. This 3-month randomized, double-blind, placebo-controlled trial assess the effects of combining daily blueberry intake with weekly exercise (BB-EX) on cardiovascular function, as well as physical activity and cognitive function, in sedentary older adults (>60 years). We will compare these effects to the same outcomes with a control group consuming a blueberry placebo (P-EX) at 0, 4, 8 and 12 weeks.


Description:

A 12-week randomized, double-blind, placebo-controlled physical activity intervention will be administered in sedentary older (>60 years) women and men randomized to either lyophilized blueberry powder, rehydrated and consumed as a beverage twice daily with meals (BB-EX; n = 25), or an indistinguishable placebo powder, taken in the same manner (placebo control; P-EX; n = 25). Vascular function (primary outcome), 24-hr ambulatory blood pressure, cognitive performance, and related secondary measures will be assessed at 0 and 12 weeks; berry and nutrient intake and function are assessed every 4 weeks; and physical activity as step counts will be continuously monitored using a mobile device (Garmin). Blood, urine (24-hr), and stool samples will be collected at 0 and 12 weeks and archived for later analysis. The 12-week study duration is based upon the timing of vascular responses seen in other trials, as well as the minimal time needed to expect a change in cognitive performance in an older adult population. The blueberry dose of 36 grams per day in a split dose consumed with meals is based on (1) a 33% increase in dose over that previously used in a longer (6-month) trial; (2) delivering the most effective dose of blueberry bioactives; and (3) reduced likelihood of any gastrointestinal symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date November 22, 2022
Est. primary completion date November 22, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age 60 and older - Overweight (BMI =25 to 35 kg/m2) - Well-controlled blood pressure (< 150/90 mmHg) - Able to speak and understand spoken and written English - Cognitively normal (Mini-Cog score 3-5) - Able to walk independently - Social security number (required for compensation) - Own a smartphone or other mobile device capable of downloading the Garmin Connect app Exclusion Criteria: - Exercise > 150 minutes/week - Unwillingness or inability to be randomized to any one of two intervention groups without knowing which (double-blind), submit to all study testing, or continuously participate in a randomly assigned diet and exercise intervention for six months. - Unwilling to restrict consumption of anthocyanin-rich foods - Unwillingness to abstain from mood altering drugs (including marijuana but excluding CBDs) for 7 days prior to baseline and endpoint testing. - Self-reported vegetarian or vegan. - Inability to complete written recording forms including journals of eating and exercise behaviors. - Inability to complete written and computerized cognitive tasks (presented in English). - Allergy or intolerance to blueberry or placebo powder ingredients Placebo ingredients include: maltodextrin, fructose, artificial blueberry flavor, natural blueberry flavor, artificial purple color (water, FD&C Red #40, FD&C Blue #1, malic acid, sodium benzoate) citric acid, and artificial red color (water, FD&C Red #40, malic acid, sodium benzoate, silica dioxide). - Gastrointestinal disorders that influence digestion and absorption of food, e.g., IBD - History of frequent urinary tract or Clostridium difficile infections - Presence of unstable, acutely symptomatic, or life-limiting illness. - Regular use of medication that interferes with the measurement of study outcomes as determined by the study physician. - Unstable use of medications, other than statins, for conditions associated with metabolic syndrome (hypertension, diabetes, dyslipidemia) during the prior 6 months or during the study. - Antibiotic use in the last 3 months. - Cigarette smoking, chewing, or use of nicotine replacement products in the past 3 months or during the course of the study. - Colonoscopy in last 2 months. - History of stomach or bowel resection (other than appendectomy), gastric bypass or other bariatric weight loss procedure effecting absorption. - History of significant weight instability (defined as > 10 pounds weight gain or loss over one month prior to study participation). - History of cancer treatment (other than melanoma skin cancer) and not "cancer-free" for at least 1 year. - History of anti-hormonal therapy (eg., for breast or prostate cancer) within the last 6 months.

Study Design


Intervention

Dietary Supplement:
Blueberry Plus Exercise (BB-EX)
Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
Blueberry Placebo Plus Exercise (P-EX)
Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University U.S. Highbush Blueberry Council

Country where clinical trial is conducted

United States, 

References & Publications (5)

Johnson SA, Figueroa A, Navaei N, Wong A, Kalfon R, Ormsbee LT, Feresin RG, Elam ML, Hooshmand S, Payton ME, Arjmandi BH. Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. J Acad Nutr Diet. 2015 Mar;115(3):369-377. doi: 10.1016/j.jand.2014.11.001. Epub 2015 Jan 8. — View Citation

Michalska A, Lysiak G. Bioactive Compounds of Blueberries: Post-Harvest Factors Influencing the Nutritional Value of Products. Int J Mol Sci. 2015 Aug 10;16(8):18642-63. doi: 10.3390/ijms160818642. — View Citation

Miller MG, Hamilton DA, Joseph JA, Shukitt-Hale B. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. Eur J Nutr. 2018 Apr;57(3):1169-1180. doi: 10.1007/s00394-017-1400-8. Epub 2017 Mar 10. — View Citation

Reis JF, Monteiro VV, de Souza Gomes R, do Carmo MM, da Costa GV, Ribera PC, Monteiro MC. Action mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human studies. J Transl Med. 2016 Nov 15;14(1):315. doi: 10.1186/s12967-016-1076-5. — View Citation

Whyte AR, Cheng N, Fromentin E, Williams CM. A Randomized, Double-Blinded, Placebo-Controlled Study to Compare the Safety and Efficacy of Low Dose Enhanced Wild Blueberry Powder and Wild Blueberry Extract (ThinkBlue) in Maintenance of Episodic and Working Memory in Older Adults. Nutrients. 2018 May 23;10(6):660. doi: 10.3390/nu10060660. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in central arterial pressure at 12 weeks Change in central arterial pressure waveform will be assessed using an automated brachial cuff. 0 to 12 weeks
Other Baseline dietary intake (Total calories) Average caloric intake will be assessed using the Diet History Questionnaire III (NCBI) food frequency questionnaire. 0 weeks
Other Baseline dietary intake (macronutrient intake) Average Macronutrient intake will be assessed using the Diet History Questionnaire III (NCBI) food frequency questionnaire. 0 weeks
Other Baseline dietary intake (micronutrient intake) Average micronutrient intake will be assessed using the Diet History Questionnaire III(NCBI) food frequency questionnaire. 0 weeks
Other Change from baseline in body weight Change in body weight will be assessed weekly using the same scale, light clothing and no shoes. 0 to 12 weeks
Other Height at baseline Height will be measured using a wall-mounted stadiometer. 0 weeks
Other Seated blood pressure at baseline Seated systolic and diastolic blood pressure will be measured, in duplicate, using an digital blood pressure monitor following 5 minutes of quiet sitting. 0 weeks
Other Change from baseline verbal memory at 12 weeks Verbal learning and memory will be assessed using the Hopkins Verbal Learning Test. 0 to 12 weeks
Other Change from baseline Executive Function at 12 weeks Executive function will be assessed using the Trail Making Test. 0 to 12 weeks
Other Change from baseline processing speed at 12 weeks Change in processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). 0 to 12 weeks
Other Change from baseline reaction time at 12 weeks Change in reaction time will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Change from baseline paired associates learning at 12 weeks Change in paired associates learning will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Change from baseline spatial working memory at 12 weeks Change in spatial working memory will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Change from baseline pattern recognition memory at 12 weeks Change in pattern recognition memory will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Change from baseline delayed matching to sample at 12 weeks Change in delayed matching to sample will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Change from baseline rapid visual information processing at 12 weeks Change in rapid visual information processing will be assessed by computerized test using CANTAB (www.cambridgecognition.com). 0 to 12 weeks
Other Adherence to diet supplementation by weekly package return count Adherence to diet supplementation will be assessed by counts of opened and unopened supplement packets returned each week. 0 to 12 weeks
Primary Change from baseline in pulse wave velocity at 12 weeks Change in carotid-femoral pulse wave velocity will be assessed using applanation tonometry, (SphygmoCor Pulse Wave Velocity System) 0 to 12 weeks
Secondary Change from baseline in cognitive flexibility at 12 weeks Change in cognitive performance will be assessed using a computerized task-switching test in which participants predictably alternate between two discrimination tasks. 0 to 12 weeks
Secondary Change from baseline in physical activity at 12 weeks Change in physical activity will be measured using a commercial activity monitor, which will be worn 24 hr/d to capture total daily steps as the measure of physical activity. 0 to 12 weeks
Secondary Change from baseline in ambulatory blood Pressure at 12 weeks Change in ambulatory blood pressure will be measured using an Ambulatory BP Monitor, with readings taken every 30 min. during the day and 60 min. at night, over a 24-hour period. 0 to 12 weeks
Secondary Change from baseline in total calories at 4, 8 and 12 weeks Total calories will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 12 weeks (0, 4, 8 and 12 weeks)
Secondary Change from baseline in macronutrient intake at 4, 8 and 12 weeks Total calories will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 12 weeks (0, 4, 8 and 12 weeks)
Secondary Change from baseline in micronutrient intake at 4, 8 and 12 weeks Total calories will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 12 weeks (0, 4, 8 and 12 weeks)
Secondary Change from baseline aerobic endurance at 4, 8, and 12 weeks Change in aerobic endurance will be determined by a 6-minute walk where subjects walk as many laps as possible in 6 minutes between cones placed 100 feet apart. 0 to 12 weeks (0, 4, 8 and 12 weeks)
Secondary Change from baseline hand grip strength at 4, 8 and 12 weeks Change in maximal upper body strength will be determined using hydraulic isometric hand dynamometer. 0 to 12 weeks (0, 4, 8 and 12 weeks)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A